This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

UCB Announces Data On Cimzia® (certolizumab Pegol) For Patients With Moderate To Severe Rheumatoid Arthritis At American College Of Rheumatology 2012 Congress

Please consult the full prescribing information in relation to other side effects, full safety and prescribing information. European SmPC date of revision June 2012.

For further Information:

Andrea Levin, Associate Director, U.S. Communications and Public Relations 770.970.8352 ,

Eimear O'Brien, Director, Brand Communications T +32.2.559.9271,

France Nivelle, Global Communications, UCBT +32.2.559.9178,

About UCB UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.


1.  Abstract 503: X. Mariette, R. van Vollenhoven, V. Bykerk, et al. Safety Update on Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long-Term Exposure. Presented at the Annual Scientific Meeting of the American College of Rheumatology (ACR) 2012.

2.  Abstract 1316: R. Fleischmann, R. van Vollenhoven, J. Vencovsky, et al. Safety and Efficacy of 4-Weekly Certolizumab Pegol in Combination with Methotrexate and as Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study. Presented at the Annual Scientific Meeting of the American College of Rheumatology (ACR) 2012.

3.  Abstract 1319: D. E. Furst, S. A. Shaikh, M. Greenwald, et al. Certolizumab Pegol Plus Methotrexate is Similarly Effective in Active Rheumatoid Arthritis Patients With or Without Secondary Non-Response to TNF Inhibitors: Post-hoc Analysis of a Phase IIIB Trial. Presented at the Annual Scientific Meeting of the American College of Rheumatology (ACR) 2012.

4.  Abstract 1318: V. Strand, O. Purcaru, R. van Vollenhoven, et al. Long-term Benefits of 4-Weekly Certolizumab Pegol and Monotherapy on Household Productivity and Social Participation in Rheumatoid Arthritis: 5 year Results from an Open Label Extension Study. Presented at the Annual Scientific Meeting of the American College of Rheumatology (ACR) 2012.

5.  Rheumatoid Arthritis, National Institute of Arthritis and Musculoskeletal and Skin Diseases. Accessed September 25, 2012 from

6.  Rheumatoid Arthritis, UCB. Accessed September 25, 2012 from

7.  Rheumatoid Arthritis, Mayo Clinic. Accessed September 25, 2012 from


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
9 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs